Literature DB >> 15293522

Infective endocarditis in maintenance hemodialysis patients: fifteen years' experience in one medical center.

Chao-Fu Chang1, Benjamin Ing-Tiau Kuo, Te-Li Chen, Wu-Chang Yang, Shou-Dong Lee, Chih-Ching Lin.   

Abstract

BACKGROUND: Infective endocarditis (IE) is a serious infectious condition, with high morbidity and mortality in hemodialysis (HD) patients. This study was undertaken to determine the IE risk factors in maintenance HD patients, and the mortality risk factors.
METHODS: We retrospectively reviewed all IE cases of maintenance HD patients at our center over the past 15 yrs (the study group). Regular HD patients without IE in the same period were used as the control group. The basic data of the two groups were analyzed to determine IE risk factors in HD patients. The in-hospital parameters of survival and mortality in the study group patients were used for mortality risk factors analysis.
RESULTS: There were 18 definite, and two possible, IE diagnoses in the study group and no cases in the 268 controls. There was no significant difference in age, sex, diabetes, hypertension, underlying malignancy, previous cerebral vascular accident (CVA) history, and calcium multiplied by phosphate product. There was a significant difference between the two groups (study group vs. controls) in pacemaker implant history (15 vs. 1.1%, p<0.01), previous heart surgery history (15 vs. 0.4%, p<0.01), congestive heart failure (CHF) (50 vs. 10.4%, p<0.05), duration on maintenance HD (12.9+/-19.1 vs. 57.9+/-42.3 months, p<0.001), serum albumin at the time of admission (2.91+/-0.40 vs. 3.96+/-0.52 g/dL, p<0.001). There were more patients dialyzed via non-cuffed dual-lumen catheters in the study group (55 vs. 0%, p<0.001), and fewer patients dialyzed via arteriovenous fistula (AVF) (25 vs. 87.7%, p<0.001). The mortality in HD patients with IE was high (60%), especially in patients with methicillin-resistant Staphylococcus aureus (MRSA) endocarditis (100%). The most common pathogen was S. aureus (n=12). MRSA was more common than methicillin-susceptible S. aureus (MSSA) (67 vs. 33%). Univariant analysis of in-hospital clinical parameters for mortality revealed no significant difference in age, diabetes, dual-lumen catheter implantation, serum albumin, time to diagnosis, and time to antibiotic use. Borderline statistical significance was noted in serum C-reactive protein (CRP) (p=0.051), and blood glucose level (p=0.056). There were more IE cases due to MRSA in the mortality group than in the survival group (8 vs. 0 cases, p=0.013), but fewer cases due to MSSA (0 vs. 4 cases, p=0.050).
CONCLUSIONS: IE should be considered in HD patients with the following risk factors, which include previous heart surgery or pacemaker implantation, shorter HD duration, and especially for patients dialyzed via dual-lumen catheters. The in-hospital clinical parameters including CRP and blood sugar level can offer information concerning prognosis. Since MRSA has increased in recent years and is associated with high mortality, strategies for prevention and treatment require development.

Entities:  

Mesh:

Year:  2004        PMID: 15293522

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  10 in total

1.  Characteristics and analysis of risk factors for mortality in infective endocarditis.

Authors:  Hakan Leblebicioglu; Hava Yilmaz; Yesim Tasova; Emine Alp; Rabin Saba; Rahmet Caylan; Mehmet Bakir; Ayhan Akbulut; Bilgin Arda; Saban Esen
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

2.  Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia.

Authors:  Bharath Raj Palraj; Larry M Baddour; Erik P Hess; James M Steckelberg; Walter R Wilson; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2015-03-25       Impact factor: 9.079

3.  Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia.

Authors:  Achim J Kaasch; Vance G Fowler; Siegbert Rieg; Gabriele Peyerl-Hoffmann; Hanna Birkholz; Martin Hellmich; Winfried V Kern; Harald Seifert
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

4.  Forensic issues in cases of fatal hemorrhage from arteriovenous dialysis access sites.

Authors:  Roger W Byard; Ross A James
Journal:  Forensic Sci Med Pathol       Date:  2007-07-10       Impact factor: 2.007

5.  Echocardiography has minimal yield and may not be warranted in Staphylococcus aureus bacteremia without clinical risk factors for endocarditis.

Authors:  G Heriot; J Yeoh; A Street; I Ratnam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-26       Impact factor: 3.267

6.  Infective endocarditis in haemodialysis patients: 16-year experience at one institution.

Authors:  Samir Baroudi; Rizwan A Qazi; Krista L Lentine; Bahar Bastani
Journal:  NDT Plus       Date:  2008-04-10

7.  Comparison of the clinical features and outcomes of infective endocarditis between hemodialysis and non-hemodialysis patients.

Authors:  Ching-Chung Hsiao; Cheng-Hao Weng; Yi-Jung Li; Hsin-Hsu Wu; Yung-Chang Chen; Yu-Ming Chen; Hsiang-Hao Hsu; Ya-Chung Tian
Journal:  Ther Clin Risk Manag       Date:  2017-05-24       Impact factor: 2.423

Review 8.  Physiopathological approach to infective endocarditis in chronic hemodialysis patients: left heart versus right heart involvement.

Authors:  Yassamine Bentata
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

9.  Mortality in patients on renal replacement therapy and permanent cardiac pacemakers.

Authors:  Gabriel Vanerio; Cristina García; Carlota González; Alejandro Ferreiro
Journal:  Int J Nephrol       Date:  2014-05-26

10.  Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis.

Authors:  Eun-Jeong Joo; Dong Ah Park; Cheol-In Kang; Doo Ryeon Chung; Jae-Hoon Song; Sang Moo Lee; Kyong Ran Peck
Journal:  Korean J Intern Med       Date:  2018-01-20       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.